Literature DB >> 9359458

Isoquinoline neurotoxins in the brain and Parkinson's disease.

T Nagatsu1.   

Abstract

Parkinson's disease is thought to be caused by some unknown endogenous or exogenous factors interacting with genetic dispositions. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is an exogenous neurotoxin producing parkinsonism in humans, monkeys and various animals as the result of monoamine oxidase type B (MAO-B)-catalyzed conversion of it to the 1-methyl-4-phenyl-pyridinium ion (MPP+), which selectively kills the nigrostriatal dopaminergic neurons. Various isoquinoline derivatives were found in the brain of patients with Parkinson's disease. Isoquinoline derivatives have neurochemical properties similar to those of MPTP and they are considered to be the endogenous neurotoxins which cause Parkinson's disease. Among them, tetrahydroisoquinoline (TIQ), 1-benzyl-TIQ, and (R)-1,2-dimethyl-5,6-dihydroxy-TIQ [(R)-N-methyl-salsolinol)] have the most potent neurotoxicity. TIQs, like MPTP, may be activated via N-methylation by N-methyltransferase and oxidation by MAO. TIQs as well as MPP+ inhibit complex I of the electron transport system in mitochondria, thereby reducing ATP formation and producing oxygen radicals. Although the properties of TIQs are similar to those of MPTP, the neurotoxicity of TIQs is weaker than that of MPTP. Since Parkinson's disease is a slowly progressing neurodegenerative disease, long term neurotoxic effects of IQs remain to be further examined in primates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359458     DOI: 10.1016/s0168-0102(97)00083-7

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  41 in total

1.  A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

Authors:  Hyo Jin Son; Ji Ae Lee; Nari Shin; Ji Hyun Choi; Jai Woong Seo; Dae Yoon Chi; Cheol Soon Lee; Eun-Mee Kim; Han Choe; Onyou Hwang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine.

Authors:  E Mazzio; K F A Soliman
Journal:  Neurotoxicology       Date:  2012-07-07       Impact factor: 4.294

3.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

4.  Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Authors:  Horace T B Ho; Yongmei Pan; Zhiyi Cui; Haichuan Duan; Peter W Swaan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-04       Impact factor: 4.030

5.  Consumption of dairy products and risk of Parkinson's disease.

Authors:  Honglei Chen; Eilis O'Reilly; Marjorie L McCullough; Carmen Rodriguez; Michael A Schwarzschild; Eugenia E Calle; Michael J Thun; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-01-31       Impact factor: 4.897

6.  Contrasting antioxidant and cytotoxic effects of peroxiredoxin I and II in PC12 and NIH3T3 cells.

Authors:  S Simzar; R Ellyin; H Shau; T A Sarafian
Journal:  Neurochem Res       Date:  2000-12       Impact factor: 3.996

7.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

Authors:  Naomi Matoh; Seigo Tanaka; Masanori Takehashi; Marek Banasik; Todd Stedeford; Eliezer Masliah; Shigehiko Suzuki; Yoshihiko Nishimura; Kunihiro Ueda
Journal:  Gene Expr       Date:  2003

Review 8.  A possible physiological role for cerebral tetrahydroisoquinolines.

Authors:  Jerzy Vetulani; Lucyna Antkiewicz-Michaluk; Irena Nalepa; Mario Sansone
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.